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Abstract
Background: The t(6;8) translocation found in rare and agressive myeloproliferative disorders
results in a chimeric gene encoding the FOP-FGFR1 fusion protein. This protein comprises the N-
terminal region of the centrosomal protein FOP and the tyrosine kinase of the FGFR1 receptor.
FOP-FGFR1 is localized at the centrosome where it exerts a constitutive kinase activity.
Results: We show that FOP-FGFR1 interacts with the large centrosomal protein CAP350 and that
CAP350 is necessary for FOP-FGFR1 localisation at centrosome. FOP-FGFR1 activates the
phosphoinositide-3 kinase (PI3K) pathway. We show that p85 interacts with tyrosine 475 of FOP-
FGFR1, which is located in a YXXM consensus binding sequence for an SH2 domain of p85. This
interaction is in part responsible for PI3K activation. Ba/F3 cells that express FOP-FGFR1 mutated
at tyrosine 475 have reduced proliferative ability. Treatment with PI3K pathway inhibitors induces
death of FOP-FGFR1 expressing cells. FOP-FGFR1 also recruits phospholipase Cγ1 (PLCγ1) at the
centrosome. We show that this enzyme is recruited by FOP-FGFR1 at the centrosome during
interphase.
Conclusion: These results delineate a particular type of oncogenic mechanism by which an ectopic
kinase recruits its substrates at the centrosome whence unappropriate signaling induces
continuous cell growth and MPD.
Background
The FGFR1 gene, located at 8p12, encodes a tyrosine
kinase receptor for members of the FGF family [1]. Chro-
mosomal rearrangements that affect FGFR1 induce an
atypical myeloproliferative disorder (MPD), characterized
by dual lympho and myeloproliferation and aggressive
evolution. In this MPD, the FGFR1 tyrosine kinase is fused
to one of several partners, including BCR [2], CEP110 [3],
ERVK [4], FOP (FGFR1 oncogene partner) [5], MYO18A
[6], TIF1 [7] and ZNF198 [8].
The FOP-FGFR1 fusion protein, in which the N-terminal
FOP protein-protein interaction sequence is fused to the
tyrosine kinase region of FGFR1, is encoded by a chimeric
gene that results from a translocation between chromo-
somal regions 8p12 and 6q27. The FOP moiety mediates
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activity triggers downstream signaling pathways including
the phosphoinositide-3 kinase (PI3K) pathway [9]. PI3K
is a heterodimer comprising a p85 regulatory subunit and
a p110 catalytic subunit that catalyzes the phosphoryla-
tion of inositol lipids from the plasma membrane. PI3K
can be activated by interaction of p85 with a phosphor-
ylated tyrosine in a YXXM motif, a consensus binding
amino acid sequence for the SH2 domains of p85 [10].
FOP-FGFR1 also binds and activates PLCγ1 [9].
The transmembrane region of FGFR1 is not conserved in
the fusion protein, which is thus unhooked from the
membrane. FOP is a centrosomal protein [11]. It interacts
with the centrosomal protein CAP350 [12]. FOP-FGFR1 is
also addressed to the centrosome [13] where it induces
phosphorylations on tyrosine residues. Other partner pro-
teins in fusion kinases, such as CEP110, NIN, PDE4DIP,
PCM1 and TRIP11 are also centrosomal proteins [14]. The
centrosome is a small organelle that control several cell
processes including microtubules organization and cell
cycle progression. Many cell cycle regulatory molecules
are localized at the centrosome [11,15]. Localization at
the centrosome may help find or recruit appropriate sub-
strates to induce cell survival and proliferation explaining
the oncogenicity of the to the fusion kinase. These sub-
strates could either be signaling molecules phosphor-
ylated at the centrosome or intrinsic centrosomal
proteins.
In this report, we have characterized the interaction of
FOP-FGFR1 with CAP350, and shown that the localiza-
tion of the tyrosine kinase at the centrosome induces the
recruitment in this specific area of two enzymatic sub-
strates, PI3K and PLCγ1.
Methods
Plasmids, cells and reagents
Ba/F3 cells hematopoietic cells were grown as described
[9]. HeLa and Cos-1 cells were grown in DMEM with 10%
fetal calf serum (FCS). Myc-tagged FOP-FGFR1 and myc-
tagged FOP-FGFR1 kinase defective (K259A) and corre-
sponding clones of stably-transfected Ba/F3 cells have
been previously described [3,5,9]. Ba/F3 stably expressing
BCR-ABL or the EPO receptor (EPO-R) are a gift from P.
Dubreuil. GFP-tagged FOP-FGFR1 was obtained by inser-
tion in pEGFP vector conferring GFP tag at the N-termi-
nus. The quickchange site-directed mutagenesis kit from
Stratagene (La Jolla, CA) was used to introduce point
mutations changing tyrosine to phenylalanine at position
511 and 475 of FOP-FGFR1 (Y511F, Y475F, and both for
DBL mutant). Each construct was verified by sequencing.
Myc-tagged CAP350 (AA 1–3117) and myc-tagged
CAP350 C-terminal domain (AA 1896–3117) constructs
were obtained by subcloning in pCS2+ with a myc tag
(pMT plasmid). The plasmid which direct the GST-SH2 N-
terminal p85α has been described [9]. Transient and sta-
ble transfections were done as described [9].
CAP350 siRNA
The following sequences were used: siCAP1, 5'-AUGAAC-
GAUAUCAGUGCUAUAUU-3' [12], siCAP2, 5'-CAG-
GUAGUAGUCAUCUUAUAAUU-3' [12], siControl, non
targeting siRNA (Dharmacon, D-001210-01). siRNA
duplexes were synthesized by Dharmacon (Lafayette,
USA) and RNAi experiments were done as previously
described [16].
Antibodies
We used monoclonal anti-myc (9E10), polyclonal anti-
FGFR1 (C-15), and polyclonal anti-PLCγ1 (1249), from
Santa Cruz Biotechology (Heidelberg, Germany), polyclo-
nal anti-p85 (06–195) from Upstate Biotechnology (Lake
Placid, NY), monoclonal anti-p85 (ab249) and anti-GFP
(ab290) from Abcam (Paris, France), polyclonal anti-
pYXXM (3821) and polyclonal anti-pPLCγ1 (2821) from
Cell Signaling (Danvers, MA), anti-γ-tubulin either mon-
oclonal (GTU-88) or polyclonal (T3559) from Sigma-
Aldrich (Lyon, France). Polyclonal anti-CAP350 antibody
was obtained by immunizing rabbits against the AA
1875–2055 domain of CAP350.
Cell lysis, immunoprecipitations, western blot and GST 
pull-down
Ba/F3 cells were starved over 7 h in RPMI containing 0.5%
FCS. For immunoprecipitation assays, cells were lysed in
NP40 1% lysis buffer. Protein extracts were incubated
with antibodies and subsequently with either protein A-
or G-agarose. Bound proteins or total protein extract were
separated as described [13] or using NuPAGE 4–12%
Novex Bis-Tris gels according to the manufacturer's
instructions (Invitrogen, Cergy Pontoise, France) for
CAP350 experiments. For GST pull-down experiments, 10
μg of bacterially product GST-p85 or GST alone were used
as previously described [9].
Cell survival assays
1.106 Ba/F3 cells were washed three times and grown in
triplicate in the absence of IL3. The number of viable cells
was measured by trypan blue exclusion. For PI3K inhibi-
tion experiments, 10 μM LY294002 (Sigma-Aldrich) was
used.
Immunofluorescence and confocal analysis
HeLa cells were grown on coverslips and starved Ba/F3
cells were centrifugated to adhere to the coverslips. Cells
were fixed for 6 min using methanol, at -20°C. Afters
washes, cells were sequentially incubated with primary
antibodies and with Cy2, Cy3 and Cy5 coupled anti-rab-
bit or anti-mouse secondary antibodies (Jackson Immu-Page 2 of 11
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using DAPI (Sigma-Aldrich). Preparation were analyzed
with Zeiss Laser Scanning confocal microscope LSM510.
Images were acquired using 63X objective and Z-series
were projected onto a single view. Images were processed
using Photoshop 8.0.1.
Results
FOP-FGFR1 fusion protein interacts with CAP350 at the 
centrosome
To better understand the role of the fusion protein at the
centrosome, we looked for centrosomal interacting pro-
teins. Since FOP interacts with CAP350 [12] we first deter-
mined that FOP-FGFR1 and CAP350 colocalize at the
centrosome in HeLa cells transiently transfected with
FOP-FGFR1 (Figure 1A). Since FOP interacts with the C-
terminal domain of CAP350, we tested the ability of FOP-
FGFR1 to interact with this region of CAP350. Experi-
ments were done with lysates from Cos-1 cells transiently
transfected with either CAP350 full length or CAP350 C-
terminal domain, and with either FOP-FGFR1 or FGFR1.
Immunoprecipitation with anti-FGFR1 antibody and
western-blot analysis with anti-CAP350 antibody showed
that FOP-FGFR1 interacts with CAP350 and that this
implies the C-terminal domain of CAP350 (Figure 1B). As
expected, FGFR1 did not co-immunoprecipitate with
CAP350 confirming that the interaction is due to the FOP
moiety of the fusion protein. The interaction is not
dependent on FOP-FGFR1 phosphorylation since the
kinase-defective FOP-FGFR1 mutant protein could also
interact with CAP350 (data not shown).
CAP350 depletion prevents FOP-FGFR1 centrosomal 
localization
CAP350 was depleted using two different oligonucle-
otides duplexes (siCAP1 and siCAP2). Depletion effi-
ciency was demonstrated by both western blotting (Figure
1C) and immunofluorescence (Figure 1D). CAP350
depletion abolished the association of FOP-FGFR1 with
centrosomes in interphase (Figure 1D) and M phase cells
(not shown).
FOP-FGFR1 recruits the p85 subunit of PI3K at the 
centrosome during interphase
We studied the localization of p85 PI3K subunit in FOP-
FGFR1-expressing cells. We found that p85 has a diffuse
localization in the cytoplasm of wild-type Ba/F3 cells,
whereas it is efficiently recruited at the centrosome by
FOP-FGFR1 in interphase (Figure 2A), and weakly during
mitosis (data not shown). This recruitment requires phos-
phorylated FOP-FGFR1 as it did not occur in cells express-
ing the kinase-defective FOP-FGFR1 K259A mutant
(Figure 2Ag) although this mutant protein also localized
to the centrosome [13]. To test the specificity of the inter-
action of p85 with FOP-FGFR1, we wondered if other
fusion kinases also recruit p85. Two other fusion kinases
tested (BCR-FGFR1, BCR-ABL) are not located at the cen-
trosome (data not shown). CEP110-FGFR1 was the only
one to provide the pYXXM motif at the centrosome (Sup-
plementary data, Figure 1Sd). However, we could not
observe p85 recruitment at the centrosome in Ba/F3 cells
expressing CEP110-FGFR1 [Additional file 1]. This sug-
gests that the pYXXM motif is not sufficient to recruit p85
at the centrosome.
FOP-FGFR1 interacts with the p85 subunit of the PI3K and 
provides a consensus binding motif at the centrosome
We next tested whether FOP-FGFR1 and p85 interact in
vivo. Using anti-FGFR1 antibody we immunoprecipitated
lysates from wild-type Ba/F3 cells or Ba/F3 cells stably
transfected with FOP-FGFR1. Western-blot analysis with
anti-p85 antibody showed that FOP-FGFR1 interacts with
p85 (Figure 2B). The p85 subunit preferentially binds a
phosphorylated tyrosine in a YXXM motif. Immunofluo-
rescence experiments with an antibody recognizing this
phosphorylated motif showed that FOP-FGFR1 provides a
consensus binding site for p85 at the centrosome (Figure
2Cd). Neither K259A mutant-expressing cells nor wild-
type Ba/F3 cells showed the same result (Figure 2Ca,g).
The fact that p85 and the phosphorylated motif for its
activation are concentrated at the centrosome suggests
that PI3K is activated at the centrosome in FOP-FGFR1-
expressing cells.
FOP-FGFR1 interacts with p85 through its tyrosine 475
The FOP-FGFR1 fusion protein contains a unique YXXM
motif, corresponding to tyrosine 475 (tyrosine 730 in the
FGFR1 sequence). We studied whether PI3K binding to
the fusion kinase occurred through this motif. We con-
structed a GFP-tagged FOP-FGFR1 mutant with a tyrosine-
to-phenylalanine substitution in the YXXM motif (named
Y475F). As controls we used a GFP-FOP-FGFR1 mutant
on tyrosine 511 (Y511F), which corresponds to the PLCγ
binding site on FGFR1, and a mutant on both tyrosines
475 and 511 (Y475F and Y511F, named DBL mutant).
GST pull-down assays showed that GST-p85 but not GST
alone associated with FOP-FGFR1. Y475F and DBL
mutants but not Y511F lacked this association (Figure
3A). We confirmed this result with endogenous p85. Co-
immunoprecipitation of p85 was tested in lysates from
HeLa cells transfected with either FOP-FGFR1 or its
mutants. FOP-FGFR1 no longer interacted with endog-
enous p85 whenever tyrosine 475 was mutated (Figure
3B).
Mutation of tyrosine 475 only partially reduces p85 
recruitment at the centrosome
Since mutation of tyrosine 475 reduces FOP-FGFR1 inter-
action with p85, we investigated whether the FOP-FGFR1
Y475F fusion protein could still induce recruitment ofPage 3 of 11
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FOP-FGFR1 interacts with CAP350 and CAP350 depletion prevents FOP-FGFR1 centrosomal localizationigure 1
FOP-FGFR1 interacts with CAP350 and CAP350 depletion prevents FOP-FGFR1 centrosomal localization. (A) 
FOP-FGFR1 colocalizes with endogenous CAP350. Immunofluorescence experiments are done on HeLa cells transiently trans-
fected with mycFOP-FGFR1. Costaining using anti-CAP350 (green) and anti-myc (red) antibody reveals colocalization at the 
centrosome of CAP350 and mycFOP-FGFR1. Scale bar 5 μm. (B) FOP-FGFR1 interacts with CAP350 in lysates from Cos-1 
cells transiently transfected with vectors expressing CAP350 C-terminus, and either FOP-FGFR1 or FGFR1. Immunoprecipita-
tions are done with anti-FGFR1 antibody and bound CAP350 is revealed by western blotting using anti-CAP350 antibody. Anti-
FGFR1 western blotting confirms the efficiency of the transfection. (C) Western blot with anti-CAP350 antibody shows 
reduced level of CAP350 in HeLa cell lysates after siRNA treatment for 48 h or 72 h with siCAP duplex as compared to sicon-
trol duplex. γ-tubulin is shown as a loading control. (D) Immunofluorescence of CAP350 depleted with siRNA CAP350 (bot-
tom) and control (top) in FOP-FGFR1 GFP HeLa cells (a, b) and anti-CAP350 antibody (b, f) and γ-tubulin antibody (c, g). 
CAP350 depleted cells lack FOP-FGFR1. Scale bar 5 μm.
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FOP-FGFR1 recruits and interacts with p85 PI3K at the centrosome in interphasic Ba/F3 cellsigure 2
FOP-FGFR1 recruits and interacts with p85 PI3K at the centrosome in interphasic Ba/F3 cells. Costaining with 
anti-p85 PI3K (red, a,d,g) and anti-γtubulin (green, b,e,h) antibodies shows the recruitment of endogenous p85 at the centro-
some, in FOP-FGFR1-expressing Ba/F3 cells, but not in wild-type (WT) or FOP-FGFR1 kinase-defective mutant (K259A) 
expressing Ba/F3 cells. Scale bar 5 μm. (B) FOP-FGFR1 interacts with endogenous p85. Immunoprecipitations with anti-FGFR1 
antibody were done on lysates from Ba/F3 cells stably transfected or not with FOP-FGFR1, and were followed by western blot-
ting with anti-p85 antibody to reveal the interaction. (C) FOP-FGFR1 provides a phosphorylated tyrosine in a YXXM motif at 
the centrosome. Costaining with anti-phospho-YXXM antibody (red, a,d,g) and anti-γtubulin antibody (green, b,e,h) shows 
phosphorylated tyrosine in a YXXM motif at the centrosome of Ba/F3-expressing FOP-FGFR1 but not in FOP-FGFR1 K259A 
or wild-type Ba/F3 cells. Scale bar 5 μm.
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Mutation of tyrosine 475 in the YXXM motif of FOP-FGFR1 reduces the interaction with p85 PI3KFigure 3
Mutation of tyrosine 475 in the YXXM motif of FOP-FGFR1 reduces the interaction with p85 PI3K. (A) Pull-
down assays were done on lysates from Cos-1 cells transiently expressing FOP-FGFR1 or its tyrosine-to-phenylalanine 
mutants on tyrosine 475, 511, or both in DBL mutant. GST-p85-SH2 PI3K or GST alone were used for pull-down, and anti-
FGFR1 antibody was used to reveal bound FOP-FGFR1 or mutant proteins. (B) Co-immunoprecipitation were done with anti-
GFP antibody on lysates from HeLa cells transiently expressing GFP-tagged FOP-FGFR1 or its mutants. Anti-p85 antibody 
reveals endogenous p85 bound to FOP-FGFR1 or to FOP-FGFR1 Y511F mutant. (C) FOP-FGFR1 Y475F mutant partially 
recruits p85 at the centrosome. Direct GFP fluorescence (green, Ca,e,i,m) of FOP-FGFR1 and its mutants, and staining with 
anti-γtubulin antibody (magenta, Cc,g,k,o), indicate that the mutants still localize at the centrosome in stably-transfected Ba/F3 
cells. Staining with anti-p85 PI3K antibody (red, Cb,f,j,n) shows the recruitment of p85 at the centrosome by the different 
mutants. Scale bar, 5 μm. (D) Staining with anti-pYXXM motif antibody (red, Db,f,j,n) indicates colocalization of this phosphor-
ylated motif with GFP-FOP-FGFR1 mutants (green, Da,e,i,n) at the centrosome, visualized with anti-γtubulin (magenta, 
Dc,g,k,o). Scale bar, 5 μm. (E) Western-blot analysis of lysates from HeLa cells either wild-type or transiently expressing FOP-
FGFR1 or its mutants. Anti-pYXXM antibody informs about the presence or not of the pYXXM motif within the different 
FOP-FGFR1 mutant proteins, detected with anti-FGFR1 antibody. Probing with anti-p85 antibody confirms that the protein 
amounts are equivalent.
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FGFR1 mutants localized at the centrosome, and showed
that recruitment of p85 at the centrosome was partially
reduced in FOP-FGFR1 Y475F cells (Figure 3Cf). Surpris-
ingly, it was also reduced in Y511F cells, which lacks the
PLCγ binding site (Figure 3Cj) and in DBL MUT cells (Fig-
ure 3Cn). These results indicate that the recruitment of
p85 is not solely due to the interaction through tyrosine
475 but implicate other sites such as tyrosine 511. Muta-
tion of FOP-FGFR1 on tyrosine 475 did not abolish the
pYXXM staining at the centrosome, although western-blot
analysis showed that the FOP-FGFR1 Y475F protein was
no longer phosphorylated on this motif (Figure 3E, D).
This suggests that other tyrosine residues, in particular
tyrosine 511, which is not in a PI3K consensus binding
motif, indirectly interact with p85 through adaptor mole-
cules and provide a phosphotyrosine in a YXXM motif at
the centrosome.
FOP-FGFR1 induces cell proliferation and survival in a 
PI3K dependent manner
FOP-FGFR1 promotes IL3-independent Ba/F3 cell sur-
vival and proliferation [9]. Because FOP-FGFR1 recruits
PI3K at the centrosome, we tested if LY294002, a specific
inhibitor of PI3K, and rapamycin, which inhibits mTOR
downstream of PI3K, affects this proliferative potential.
Cells were starved of IL3 and cell survival was monitored
over 120 h using trypan blue dye exclusion assay.
LY294002 induced the death of the FOP-FGFR1-express-
ing cells, suggesting that the PI3K pathway is required for
the survival and proliferative effects of the fusion protein
(Figure 4A). Ba/F3 cells expressing the erythropoietin
receptor (EPO-R) or BCR-ABL, which do not rely solely on
the PI3K pathway for growth, were able to survive (Figure
4A). FOP-FGFR1 Y475F cells failed to proliferate, confirm-
ing that PI3K interaction with the tyrosine 475 of FOP-
FGFR1 is essential for the cellular effects of the oncogenic
kinase (Figure 4B). Mutation of tyrosine 511 also strongly
affected cell survival and proliferation (Figure 4B). This
effect could be due to an indirect interaction with PI3K
and/or to a specific PLCγ1-associated pathway.
FOP-FGFR1 recruits and activates PLCγ1 at the 
centrosome
The interaction of PLCγ1 with FOP-FGFR1 is mediated by
tyrosine 511 [9]. We determined that PLCγ1 localizes at
the spindle poles and along the microtubules during
mitosis in Ba/F3 wt cells and in cells expressing the kinase-
deficient K259A mutant (arrow Figure 5Ad) and that FOP-
FGFR1 induces a strong recruitment of PLCγ1 at the cen-
trosome during interphase (arrowheads, Figure 5Aa).
Mutation of tyrosine 475 did not affect this recruitment
(Figure 5Bf), whereas it was reduced by mutation of tyro-
sine 511 (Figure 5Bj). However, the staining remained
strong during mitosis, and weak in some rare cells during
interphase (this might concern the cells about to enter M
phase), as well as in kinase-defective control cells (arrow-
heads, Figure 5Ad). Then, we wondered if centrosomal
PLCγ1 becomes activated. We showed that only FOP-
FGFR1 and its Y475F mutant phosphorylate PLCγ1 (Fig-
ure 5C). Hence, mutation on tyrosine 511 abolishes both
recruitment at the centrosome and activation of PLCγ1.
Discussion
We have shown here that the FOP-FGFR1 oncogenic tyro-
sine kinase encounters or recruits different partners at the
PI3K pathway is essential for FOP-FGFR1 expressing cell survival and proliferationFigure 4
PI3K pathway is essential for FOP-FGFR1 expressing cell survival and proliferation. (A) LY294002 or rapamycin 
treatment abolishes FOP-FGFR1 effect on cell survival. Ba/F3 cells were washed free of IL3 and 1.106 cells were plated in tripli-
cates in IL3 free medium, in the absence or presence of LY294002 10 μM, rapamycin 10 nM or equivalent amount of DMSO. 
Viable cells were counted over a 120 h-period. Results are means of three independent experiments. (B) The same survival 
experiment was done on Ba/F3 cells stably expressing either FOP-FGFR1 or its mutants.Page 7 of 11
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FOP-FGFR1 induces PLCγ1 recruitment at the centrosome during interphase and activates PLCγ1igure 5
FOP-FGFR1 induces PLCγ1 recruitment at the centrosome during interphase and activates PLCγ1. (A) Immun-
ofluorescence experiments with anti-PLCγ1 antibody (red, Aa,d), and anti-γtubulin (green, Ab,c) shows PLCγ1 at the centro-
some and spindle microtubules of both FOP-FGFR1 or FOP-FGFR1 K259A- expressing cells during mitosis (arrows), and a 
specific recruitment at the centrosome of interphasic FOP-FGFR1-expressing cells (arrowhead). Scale bar, 5 μm. (B) Direct 
GFP fluorescence (green, Ba,e,i,m) of FOP-FGFR1 and its mutants, staining with anti-γtubulin antibody (magenta, Bc,g,k,o), anti-
PLCγ1 antibody (red, Bb,f,j,n) shows recruitment of PLCγ1 at the centrosome by the different mutants. Scale bar, 5 μm. (C) 
Western-blot analysis with anti-pPLCγ1 antibody reveals activation of PLCγ1. Lysates from wild type Ba/F3 cells or Ba/F3 cells 
stably expressing FOP-FGFR1 or its mutants were used. Anti-PLCγ1 antibody was used for loading control.
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with CAP350. CAP350 is essential for FOP localization at
the centrosome [12]. CAP350 is a large centrosomal pro-
tein with many coiled-coil motifs [17]. It is phosphor-
ylated during mitosis and has an ATP/GTP-binding site
motif. Little is known about CAP350 functions at the cen-
trosome. CAP350 and FOP form a complex required for
anchoring microtubules at the centrosome [12]. CAP350
could serve as a scaffold for anchoring a large number of
regulatory molecules, including an ectopic fusion protein.
The presence of a constitutive tyrosine kinase activity on
this platform could alter the function of centrosomal pro-
teins involved in cell cycle regulation, including CAP350
itself. It is not known whether CAP350 also interacts with
CEP110, the centrosomal partner of the CEP110-FGFR1
fusion kinase found in MPD with t(8;9). However, our
yeast two-hybrid screens does not suggest it does (data not
shown).
We next showed that FOP-FGFR1 interacts with p85 and
that the mutation of tyrosine 475 in the FOP-FGFR1
kinase domain reduces this interaction. The correspond-
ing tyrosine in the FGFR1 sequence is tyrosine 730 which
has never been described as phosphorylated [18] and for
which no interacting substrate has been reported. The
PI3K pathway is involved whenever FGFR1 is stimulated.
PI3K seems to be activated mainly through the interaction
with the FGFR1 juxtamembrane domain, due to adaptor
proteins providing the consensus binding motif for p85,
such as GAB1 [19,20]. However, this domain is disrupted
in FOP-FGFR1. Our results suggest that tyrosine 475 is
phosphorylated in the FOP-FGFR1 protein and provides a
de novo binding motif for p85 allowing PI3K interaction
and activation. We propose that it is the sustained kinase
activity of FOP-FGFR1 compared to the physiologic inter-
mittent activation of FGFR1, which allows tyrosine 475
phosphorylation. However, this interaction is only one
way to PI3K activation. Other tyrosines, such as Y511,
must be involved in an indirect interaction with p85.
Tyrosine 511 could indirectly interact with p85 through
adaptor molecules such as SHC. Another possibility is
that FOP protein partners such as CAP350 or others may
somehow participate in recruiting PI3K.
PI3K is usually associated with the plasma membrane,
downstream of tyrosine kinases. We show here that p85
can be recruited at the centrosome upon oncogenic sign-
aling. This may also occur in physiological conditions.
Stimulation of cells expressing the insulin receptor with
insulin triggers the association of PI3K with γ-tubulin,
suggesting that PI3K is recruited at the centrosome [21].
The presence of the p85 subunit at the centrosome sug-
gests that lipid products might be concentrated in this
structure. Although large cytosolic pools of PI3K have
been described [22,23], PI3K activity should eventually
involve interaction with a membrane, since both the sub-
strate and products of PI3K are membrane constituents.
Under stimulation of the insulin receptor, PI3K is associ-
ated with intracellular membranes and to a lesser extent
with the plasma membrane [24]. Since the Golgi aparatus
is connected to the centrosome, it is possible that centro-
somal PI3K associates with vesicles derived from the Golgi
membranes. Because p85 recruitment by FOP-FGFR1 is
not strictly restricted to the centrosome, it is also possible
that p85 localizes in the centrosome/Golgi area.
The role of PI3K at the centrosome remains to be deter-
mined. We have previously demonstrated that FOP-
FGFR1 induces continuous entry in S phase [13,14].
Another study has suggested that PI3K is required for cen-
trosome duplication and/or separation, which occurs dur-
ing the G1 and S phase [25]. The CDK2-cyclin E complex
is required for both DNA replication and centrosome
duplication [26,27], and PI3K can enhance phosphoryla-
tion and activation of CDK2 [28]. Thus, PI3K activated at
the centrosome by FOP-FGFR1 could alter the phosphor-
ylation level of centrosomal components such as CDK2
and trigger centrosome duplication in G1/S phase of the
cell cycle.
FOP-FGFR1 activates and recruits PLCγ1 at the centro-
some. Mutation of Y511 PLCγ1-binding site affects cell
survival and proliferation and binding of PCLγ1. This sug-
gests that PLCγ interaction and activation is also impor-
tant for proliferation and survival of FOP-FGFR1-
expressing Ba/F3 cells and that PI3K and PLCγ1 might act
synergistically. This is in agreement with the fact that
Y511F mutant FOP-FGFR1 fails to recruit p85 at the cen-
trosome. PI3K and PLCγ1 share common downstream
substrates such as phosphatidylinositol-4,5-biphosphate
(PIP2) and protein kinase C (PKC). An isoform of PKC,
PKCε, localizes at the centrosome in a hypophosphor-
ylated state [29]. Interestingly, both downtream effectors
of PI3K and PLCγ1 phosphorylate PKCε on complemen-
tary sites to induce its activation [30].
Conclusion
FOP-FGFR1, landing on CAP350 at the centrosome, can
recruit and hence activate its main known substrates PI3K
and PLCγ1 at this organelle (Figure 6). These enzymes
may in turn activate both centrosomal proteins and
downstream signaling proteins. Our results show how an
oncogene may pervert physiological cell processes to its
profit. Study of the oncogenic FOP-FGFR1 protein could
help understand physiological centrosomal processes as
well as leukemogenesis.
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Schematic representation of the centrosome depicting FOP-FGFR1 and its partnersFigure 6
Schematic representation of the centrosome depicting FOP-FGFR1 and its partners. FOP-FGFR1 interacts with 
the centrosomal protein CAP350 through the FOP moiety. From this platform, the centrosomal FOP-FGFR1 protein recruits 
PI3K in particular through interaction with Y475 of FOP-FGFR1, and recruits PLCγ1 through interaction with Y511. The PI3K 
and PLCγ1 pathways are activated and are important to induce the effects of FOP-FGFR1 at the centrosome.Page 10 of 11
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Additional files 1
CEP110-FGFR1 localizes at the centrosome and provides a centrosomal 
pYXXM motif at the centrosome. Ba/F3 cells stably expressing CEP110-
FGFR1 are stained with anti-γ tubulin antibody (green, b,e,h) to localize 
the centrosome. Costaining with anti-FGFR1, anti-pYXXM and anti-p85 
antibodies (red, a,d,g) allows to localize respectively CEP110-FGFR1, 
phosphotyrosines in a YXXM motif and p85 PI3K in the cells. Scale bar, 
5 μm.
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